Less invasive ablation may rival surgery for liver tumors
NCT ID NCT07559851
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 151 patients with colorectal cancer that spread to the liver (tumors 5 cm or smaller). Researchers compared two treatments: ablation (using heat to destroy tumors) plus chemotherapy, versus surgery to remove the tumors plus chemotherapy. The goal was to see which approach led to longer time without the cancer growing. The study found that both treatments had similar outcomes, suggesting ablation could be a good alternative to surgery for some patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- microwave ablation
- What this could lead to
- If this study shows ablation is as effective as surgery, it could offer a less invasive option for patients with colorectal liver metastases.
- What could go wrong
- This is a retrospective study, not a randomized trial, so results may be biased. The findings need confirmation in larger, prospective studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
151 people
The number who actually took part.
- Started
-
Jan 2018
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This retrospective study included patients with colorectal liver metastases (≤5 lesions, ≤5 cm) who underwent thermal ablation with systemic therapy or liver resection with systemic therapy at four hospitals between January 2018 and April 2023.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 85 years. * Primary tumor resected with R0 resection and pathological confirmation of colorectal adenocarcinoma. * Liver metastasis confirmed by any two of the following examinations: contrast-enhanced CT, enhanced MRI, CEUS, PET-CT, or pathology. * Liver metastases with maximum diameter ≤ 5 cm and ≤ 5 lesions. Exclusion Criteria: * History of other local treatments for liver metastasis prior to ultrasound-guided microwave ablation/liver resection. * With concurrent extrahepatic metastases. * With concurrent other malignancies. * With incomplete clinical data.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal liver metastasis (CRLM) are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, 130012, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.